TipRanks
Neuphoria Therapeutics (MX:BNOXN)
:BNOXN
Mexico Market
BNOXN
Neuphoria Therapeutics
RESEARCH TOOLSreports

Neuphoria Therapeutics (BNOXN) Income Statement

0 Followers

Neuphoria Therapeutics Income Statement

Last quarter (Q4 2026), Neuphoria Therapeutics's total revenue was AU$1.17M, a decrease of -111.21% from the same quarter last year. In Q4, Neuphoria Therapeutics's net income was AU$-4.90M. See Neuphoria Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Jun 26Jun 25Jun 24Jun 23Jun 22
Total Revenue
$ 1.17M$ 15.65M$ 0.00AU$ 0.00AU$ 383.16K
Gross Profit
$ 511.21K$ 14.99M$ -662.99KAU$ -671.48KAU$ -9.98M
Operating Expenses
$ 10.32M$ 16.12M$ 17.89MAU$ 33.09MAU$ 23.74M
Depreciation and Amortization
$ 662.96K$ 1.01M$ 992.56KAU$ 998.17KAU$ 1.61M
EBITDA
$ -9.15M$ -121.90K$ -25.65MAU$ -31.45MAU$ -30.25M
Operating Income
$ -9.81M$ -1.13M$ -26.79MAU$ -33.09MAU$ -31.02M
Other Income/Expenses
$ -3.78M$ 291.09K$ 2.31MAU$ 695.55KAU$ -886.03K
Pretax Income
$ -13.59M$ -838.00K$ -15.58MAU$ -32.39MAU$ -31.90M
Net Income
$ -13.45M$ -369.63K$ -15.49MAU$ -32.18MAU$ -22.94M
Per Share Metrics
Basic EPS
$ -3.06$ -0.23$ -0.10AU$ -0.24AU$ -0.20
Diluted EPS
$ -3.06$ -0.23$ -0.10AU$ -0.24AU$ -0.20
Weighted Average Shares Outstanding
 4.40M 1.62M 149.80M 122.39M 112.78M
Weighted Average Shares Outstanding (Diluted)
 4.40M 1.62M 149.80M 122.39M 112.78M

Neuphoria Therapeutics Earnings and Revenue History